Abnova (Taiwan) Corporation (TPE:4133)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.05
+0.05 (0.22%)
Mar 24, 2026, 1:30 PM CST
Market Cap1.40B -24.1%
Revenue (ttm)351.30M -1.1%
Net Income-1.14M
EPS-0.02
Shares Out60.55M
PE Ration/a
Forward PEn/a
Dividend0.11 (0.49%)
Ex-Dividend DateJun 16, 2025
Volume34,521
Average Volume112,506
Open23.10
Previous Close23.00
Day's Range22.90 - 23.25
52-Week Range21.70 - 35.10
Beta0.47
RSI39.07
Earnings DateFeb 26, 2026

About Abnova (Taiwan)

Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company’s products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating r... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 4133
Full Company Profile

Financial Performance

Financial Statements